期刊
EPILEPSY RESEARCH
卷 85, 期 1, 页码 123-127出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.eplepsyres.2009.02.019
关键词
Traumatic brain injury; Epilepsy; Rimonabant; CB1
资金
- US National Institutes of Health [NS35915]
- UCI Medical Scientist Training Program
Effective prophylaxis for post-traumatic epilepsy currently does not exist, and clinical trials using anticonvulsant drugs have yielded no long-term antiepileptogenic effects. We report that a single, rapid post-traumatic application of the proconvulsant cannabinoid type-1 (CB1) receptor antagonist SR141716A (Rimonabant-Acomplia (R)) abolishes the long-term increase in seizure susceptibility caused by head injury in rats. These results indicate that, paradoxically, a seizure-enhancing drug may disrupt the epileptogenic process if applied within a short therapeutic time window. (C) 2009 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据